BioCryst Pharmaceuticals, Inc. (BCRX)
7.63
-0.61
(-7.40%)
USD |
NASDAQ |
Nov 05, 16:00
7.50
-0.13
(-1.70%)
After-Hours: 20:00
BioCryst Pharmaceuticals Net Income (TTM) : -359.66M for Sept. 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | -359.66M |
| June 30, 2026 | -384.67M |
| March 31, 2026 | -457.98M |
| December 31, 2025 | 263.86M |
| September 30, 2025 | -8.779M |
| June 30, 2025 | -35.71M |
| March 31, 2025 | -53.47M |
| December 31, 2024 | -88.88M |
| September 30, 2024 | -123.82M |
| June 30, 2024 | -145.93M |
| March 31, 2024 | -208.58M |
| December 31, 2023 | -226.54M |
| September 30, 2023 | -236.35M |
| June 30, 2023 | -242.72M |
| March 31, 2023 | -226.25M |
| December 31, 2022 | -247.12M |
| September 30, 2022 | -193.35M |
| June 30, 2022 | -209.64M |
| March 31, 2022 | -193.97M |
| December 31, 2021 | -184.06M |
| September 30, 2021 | -226.78M |
| June 30, 2021 | -214.09M |
| March 31, 2021 | -209.50M |
| December 31, 2020 | -182.81M |
| September 30, 2020 | -124.94M |
| Date | Value |
|---|---|
| June 30, 2020 | -116.42M |
| March 31, 2020 | -115.44M |
| December 31, 2019 | -108.90M |
| September 30, 2019 | -133.71M |
| June 30, 2019 | -125.71M |
| March 31, 2019 | -106.53M |
| December 31, 2018 | -101.25M |
| September 30, 2018 | -93.36M |
| June 30, 2018 | -78.90M |
| March 31, 2018 | -77.34M |
| December 31, 2017 | -65.78M |
| September 30, 2017 | -50.74M |
| June 30, 2017 | -47.14M |
| March 31, 2017 | -46.53M |
| December 31, 2016 | -55.14M |
| September 30, 2016 | -68.78M |
| June 30, 2016 | -71.87M |
| March 31, 2016 | -50.69M |
| December 31, 2015 | -43.02M |
| September 30, 2015 | -36.56M |
| June 30, 2015 | -30.67M |
| March 31, 2015 | -50.22M |
| December 31, 2014 | -45.19M |
| September 30, 2014 | -38.95M |
| June 30, 2014 | -38.22M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Amgen, Inc. | 9.391B |
| Halozyme Therapeutics, Inc. | 413.60M |
| Neurocrine Biosciences, Inc. | 702.50M |
| Agenus, Inc. | 91.94M |
| Anika Therapeutics, Inc. | -3.121M |